Autologous, genetically engineered anti-CD19 chimeric antigen receptor (CAR) T-cell therapy that co-expresses and secretes human interleukin-18 (armored CAR). Designed for relapsed/refractory CD19+ non-Hodgkin lymphomas to mediate antigen-specific cytotoxicity against B-cell malignancies, while IL-18 enhances CAR-T expansion/persistence and induces a Th1-skewed proinflammatory environment (enhancing IFN-γ and activating NK cells and macrophages). Administered as a single IV infusion with dose escalation.